The Latest Breaking News from Verona Pharma

This pharmaceutical leaders offers a combination of growth, income, and innovation.

Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative.

Summary Verona Pharma (VRNA) shows strong technical indicators with a 54.89% gain since 11/19, driven by Barchart's Trend Seeker buy signal. The company focuses on developing ensifentrine for respiratory diseases, currently in Phase 3 trials, with multiple inhaler formulations. Barchart's technical indicators highlight 100% buy signals, a 222.12% gain in...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

A strong pipeline of products could potentially transform these companies, but there are risks.

Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high.

Upgrades

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

  Verona Pharma (NASDAQ:VRNA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.